Notizie AIOM – anno XV n. 633

13 Giugno 2017

ASCO Partners With FDA to Incorporate Real-World Evidence into Drug Decisions

June 9, 2017 - In recognition of the potential for real-world evidence (RWE) to significantly improve the way patients with cancer are treated, CancerLinQ has formed new partnerships with the US government that are expected to coordinate the sharing of patient data and incorporate ...
Leggi tutto

13 Giugno 2017

FDA Requests Removal of Oxymorphone Hydrochloride for Risks Related to Abuse

June 9, 2017 - On June 8,the U.S. Food and Drug Administration (FDA) requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated oxymorphone hydrochloride, from the market. After careful consideration, the agency is seeking removal based on its concern ...
Leggi tutto

13 Giugno 2017

Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma

Mammalian target of rapamycin inhibitors may induce pneumonitis. We analysed the association of pneumonitis with outcomes in everolimus treated metastatic renal cell carcinoma (mRCC) patients. Eighty-five mRCC patients received everolimus at Helsinki University Hospital ...
Leggi tutto

13 Giugno 2017

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer. In this randomised, double-blind, active-controlled, phase 3 equivalence ...
Leggi tutto

13 Giugno 2017

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer

Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients ...
Leggi tutto

12 Giugno 2017

European Commission Approves Nivolumab for Previously Treated, Locally Advanced, Unresectable or Metastatic Urothelial Cancer

June 8, 2017 - On June 2, the European Commission (EC) approved nivolumab for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. This makes nivolumab the first immuno-oncology agent ...
Leggi tutto

12 Giugno 2017

9 giugno 2017 – Per la lotta al cancro non solo farmaci innovativi, ma anche prevenzione, informazione e diagnosi precoce

12 Giugno 2017

9 giugno 2017 – Comunicazione EMA su docetaxel

12 Giugno 2017

7 giugno 2017 – Determinazione AIFA n° 1023/2017

12 Giugno 2017

ASCO Congratulates NIH Director Francis Collins on Remaining in Critical Leadership Position

June 8, 2017 - ASCO President Bruce E. Johnson, MD, FASCO, released the following statement today: “ASCO congratulates Francis S. Collins, MD, PhD, on the announcement of his continued service as the Director of the National Institutes of Health (NIH). A renowned researcher ...
Leggi tutto

LAVORIAMO CON

News

MELANOMA, IN ITALIA OGNI ANNO PIU’ DI 12.900 CASI. IMI: “PERSONALIZZARE LA PREVENZIONE E I TRATTAMENTI”

TUMORE DEL SENO: QUATTRO PAZIENTI SU DIECI TEMONO DI PERDERE IL LAVORO EUROPA DONNA ITALIA: ‘IL CANCRO NON COMPROMETTA LE OPPORTUNITÀ PROFESSIONALI’

SALUTE DEL CERVELLO, 1 PERSONA SU 3 VIVE CON UN DISTURBO NEUROLOGICO ARRIVA BRAINSPACE HOUSE: “IMPORTANTE PARLARE DI PREVENZIONE CON ADULTI E BAMBINI”

GIORNATA MONDIALE DEL MALATO REUMATICO: NEL 2025 OLTRE 1,18 MILIONI DI CERTIFICATI PER PATOLOGIE MUSCOLO-SCHELETRICHE

IN ITALIA 55MILA DONNE VIVONO CON UN TUMORE AL SENO METASTATICO. ‘SERVE UN PDTA NAZIONALE UNIFORME, INTEGRATO E CENTRATO SULLA PERSONA’

TUMORE SENO METASTATICO: SERVONO PERCORSI SPECIFICI IN TUTTE LE BREAST UNIT. EUROPA DONNA ITALIA: «GARANTIRE PERCORSI DEDICATI, CON STANDARD DI QUALITÀ OMOGENEI SU TUTTO IL TERRITORIO NAZIONALE».

TUMORE SENO METASTATICO TRIPLO NEGATIVO, IN ITALIA OLTRE 8.200. CASI AIGOM: “TUTTE LE PAZIENTI SIANO SOTTOPOSTE AL TEST DEL BRCA”

Notizie AIOM – anno XV n. 633

ASCO Partners With FDA to Incorporate Real-World Evidence into Drug Decisions

FDA Requests Removal of Oxymorphone Hydrochloride for Risks Related to Abuse

Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer

European Commission Approves Nivolumab for Previously Treated, Locally Advanced, Unresectable or Metastatic Urothelial Cancer

9 giugno 2017 – Per la lotta al cancro non solo farmaci innovativi, ma anche prevenzione, informazione e diagnosi precoce

9 giugno 2017 – Comunicazione EMA su docetaxel

7 giugno 2017 – Determinazione AIFA n° 1023/2017

ASCO Congratulates NIH Director Francis Collins on Remaining in Critical Leadership Position